|
1
|
Berthold F, Boos J, Burdach S, Erttmann R,
Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe
M, et al: Myeloablative megatherapy with autologous stem-cell
rescue versus oral maintenance chemotherapy as consolidation
treatment in patients with high-risk neuroblastoma: A randomised
controlled trial. Lancet Oncol. 6:649–658. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park JR, Eggert A and Caron H:
Neuroblastoma: Biology, prognosis, and treatment. Hematol Oncol
Clin North Am. 24:65–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Westhoff MA, Faham N, Marx D, Nonnenmacher
L, Jennewein C, Enzenmüller S, Gonzalez P, Fulda S and Debatin KM:
Sequential dosing in chemosensitization: Targeting the
PI3K/Akt/mTOR pathway in neuroblastoma. PLoS One. 8:e831282013.
View Article : Google Scholar
|
|
4
|
Brodeur GM: Neuroblastoma: Biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Opel D, Poremba C, Simon T, Debatin KM and
Fulda S: Activation of Akt predicts poor outcome in neuroblastoma.
Cancer Res. 67:735–745. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fulda S: The PI3K/Akt/mTOR pathway as
therapeutic target in neuroblastoma. Curr Cancer Drug Targets.
9:729–737. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Izycka-Swieszewska E, Drozynska E, Rzepko
R, Kobierska-Gulida G, Grajkowska W, Perek D and Balcerska A:
Analysis of PI3K/AKT/mTOR signalling pathway in high risk
neuroblastic tumours. Pol J Pathol. 61:192–198. 2010.
|
|
9
|
Roper J, Richardson MP, Wang WV, Richard
LG, Chen W, Coffee EM, Sinnamon MJ, Lee L, Chen PC, Bronson RT, et
al: The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor
regression in a genetically engineered mouse model of PIK3CA
wild-type colorectal cancer. PLoS One. 6:e251322011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen X, Zhao M, Hao M, Sun X, Wang J, Mao
Y, Zu L, Liu J, Shen Y, Wang J, et al: Dual inhibition of PI3K and
mTOR mitigates compensatory AKT activation and improves tamoxifen
response in breast cancer. Mol Cancer Res. 11:1269–1278. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zito CR, Jilaveanu LB, Anagnostou V, Rimm
D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM and Chao HH:
Multilevel targeting of the phosphatidylinositol-3-kinase pathway
in non-small cell lung cancer cells. PLoS One. 7:e313312012.
View Article : Google Scholar
|
|
12
|
Ribback S, Cigliano A, Kroeger N, Pilo MG,
Terracciano L, Burchardt M, Bannasch P, Calvisi DF and Dombrowski
F: PI3K/AKT/mTOR pathway plays a major pathogenetic role in
glycogen accumulation and tumor development in renal distal tubules
of rats and men. Oncotarget. 6:13036–13048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Manara MC, Nicoletti G, Zambelli D,
Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM,
García-Echeverría C, Mercuri M, et al: NVP-BEZ235 as a new
therapeutic option for sarcomas. Clin Cancer Res. 16:530–540. 2010.
View Article : Google Scholar
|
|
14
|
Chanthery YH, Gustafson WC, Itsara M,
Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G,
Matthay KK, et al: Paracrine signaling through MYCN enhances
tumor-vascular interactions in neuroblastoma. Sci Transl Med.
4:115ra32012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li CY, Wang EQ, Cheng Y and Bao JK:
Oridonin: An active diterpenoid targeting cell cycle arrest,
apoptotic and autophagic pathways for cancer therapeutics. Int J
Biochem Cell Biol. 43:701–704. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Z, Ouyang L, Peng H and Zhang WZ:
Oridonin: Targeting programmed cell death pathways as an
anti-tumour agent. Cell Prolif. 45:499–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu DL, Bu HQ, Jin HM, Zhao JF, Li Y and
Huang H: Enhancement of the effects of gemcitabine against
pancreatic cancer by oridonin via the mitochondrial
caspase-dependent signaling pathway. Mol Med Rep. 10:3027–3034.
2014.PubMed/NCBI
|
|
18
|
Guo Y, Shan Q, Gong Y, Lin J, Yang X and
Zhou R: Oridonin in combination with imatinib exerts synergetic
anti-leukemia effect in Ph+ acute lymphoblastic leukemia
cells in vitro by inhibiting activation of LYN/mTOR signaling
pathway. Cancer Biol Ther. 13:1244–1254. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang Y, Hamed HA, Cruickshanks N, Fisher
PB, Grant S and Dent P: Obatoclax and lapatinib interact to induce
toxic autophagy through NOXA. Mol Pharmacol. 81:527–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta
S, Thor RK, Damoiseaux R, Liang C and Huang J: Combination of
Rad001 (everolimus) and propachlor synergistically induces
apoptosis through enhanced autophagy in prostate cancer cells. Mol
Cancer Ther. 11:1320–1331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fong A and Park JR: High-risk
neuroblastoma: A therapy in evolution. Pediatr Hematol Oncol.
26:539–548. 2009. View Article : Google Scholar
|
|
22
|
National Cancer Institute. Board PDQPTE:
Neuroblastoma Treatment (PDQ(R)): Health Professional Version. PDQ
Cancer Information Summaries. National Cancer Institute (US);
Bethesda (MD): 2002, http://www.cancer.gov/publications/pdq/information-summaries/adult-treatment.
Accessed, January 14, 2016
|
|
23
|
Pearson AD, Pinkerton CR, Lewis IJ, Imeson
J, Ellershaw C and Machin D; European Neuroblastoma Study Group;
Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom
Children's Cancer Study Group). High-dose rapid and standard
induction chemotherapy for patients aged over 1 year with stage 4
neuroblastoma: A randomised trial. Lancet Oncol. 9:247–256. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kreissman SG, Seeger RC, Matthay KK,
London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL,
Diller L, et al: Purged versus non-purged peripheral blood
stem-cell transplantation for high-risk neuroblastoma (COG A3973):
A randomised phase 3 trial. Lancet Oncol. 14:999–1008. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H, Jin X, Zhang Z, Xing Y and Kong X:
Inhibition of autophagy enhances apoptosis induced by the
PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Cell Biochem Funct. 31:427–433. 2013. View
Article : Google Scholar
|
|
26
|
Echeverry N, Ziltener G, Barbone D, Weder
W, Stahel RA, Broaddus VC and Felley-Bosco E: Inhibition of
autophagy sensitizes malignant pleural mesothelioma cells to dual
PI3K/mTOR inhibitors. Cell Death Dis. 6:e17572015. View Article : Google Scholar :
|
|
27
|
Ji Y, Di W, Yang Q, Lu Z, Cai W and Wu J:
Inhibition of autophagy increases proliferation inhibition and
apoptosis induced by the PI3K/mTOR inhibitor NVP-BEZ235 in breast
cancer cells. Clin Lab. 61:1043–1051. 2015.PubMed/NCBI
|
|
28
|
Jiang X, Overholtzer M and Thompson CB:
Autophagy in cellular metabolism and cancer. J Clin Invest.
125:47–54. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fulda S and Kögel D: Cell death by
autophagy: Emerging molecular mechanisms and implications for
cancer therapy. Oncogene. 34:5105–5113. 2015. View Article : Google Scholar
|
|
30
|
Rodríguez CE, Reidel SI, Bal de Kier Joffé
ED, Jasnis MA and Fiszman GL: Autophagy protects from
trastuzumab-induced cytotoxicity in HER2 overexpressing breast
tumor spheroids. PLoS One. 10:e01379202015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song J, Qu Z, Guo X, Zhao Q, Zhao X, Gao
L, Sun K, Shen F, Wu M and Wei L: Hypoxia-induced autophagy
contributes to the chemoresistance of hepatocellular carcinoma
cells. Autophagy. 5:1131–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Toshima T, Shirabe K, Matsumoto Y, Yoshiya
S, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T and Maehara Y:
Autophagy enhances hepatocellular carcinoma progression by
activation of mitochondrial β-oxidation. J Gastroenterol.
49:907–916. 2014. View Article : Google Scholar
|
|
33
|
Goussetis DJ, Altman JK, Glaser H, McNeer
JL, Tallman MS and Platanias LC: Autophagy is a critical mechanism
for the induction of the antileukemic effects of arsenic trioxide.
J Biol Chem. 285:29989–29997. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Crazzolara R, Cisterne A, Thien M, Hewson
J, Baraz R, Bradstock KF and Bendall LJ: Potentiating effects of
RAD001 (Everolimus) on vincristine therapy in childhood acute
lymphoblastic leukemia. Blood. 113:3297–3306. 2009. View Article : Google Scholar : PubMed/NCBI
|
